The increased expression of the CYP2E1 and CYP4A11 genes in steatosis, with a down-regulation of the CYP2E1 P450 and elevated CYP4A11 in the progression of MASLD indicate the differential role of these genes. This evidence concerns the gene CYP2B6 and metabolic dysfunction-associated steatotic liver disease.